Kidney Cancer

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma

Cristian Udovicich a,b, Jason Callahanc, Mathias Bresseld, Wee Loon Onga,e,f, Marlon Pererag,h, Ben Tran b,i, Arun Azad b,i, Shankar Harana, Daniel Moon k,l, Sarat Chander a,m, Mark Shaw a, Renu Eapen l,n, Jeremy Goad l,o,p, Nathan Lawrentschuk l,q,r, Declan G. Murphy l, Michael Hofman b,c, Shankar Siva a,b, *

a Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; b Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia; c Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; d Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia; e Alfred Health Radiation Oncology, Melbourne, Australia; f Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Australia; g Austin Health, Department of Surgery, The University of Melbourne, Melbourne, Australia; h Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; i Centre for Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; j Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Australia; k Royal Melbourne Hospital Clinical School, The University of Melbourne, Melbourne, Australia; l Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; m Clinical Pathology, The University of Melbourne, Melbourne, Australia; n Department of Urology, Austin Health & Olivia Newton John Cancer Centre, Heidelberg, Australia; o Department of Urology, St. Vincent’s Health, Fitzroy, Australia; p Medical Education, The University of Melbourne, Melbourne, Australia; q Department of Urology, The Royal Melbourne Hospital, Parkville, Australia; r Department of Surgery, The University of Melbourne, Melbourne, Australia

Article info

Article history:
Accepted August 4, 2022

Associate Editor:
M. Carmen Mir

Keywords:
Renal cell carcinoma
Oligometastatic
Prostate-specific membrane antigen
Positron emission tomography/computed tomography
Metastasis-directed therapy
Management change
Impact

Abstract

Background: Prostate-specific membrane antigen (PSMA) is overexpressed in the neovasculature of renal cell carcinoma (RCC). However, there remains limited evidence regarding the use of PSMA positron emission tomography/computed tomography (PET/CT) in RCC.

Objective: To assess the impact of PSMA PET/CT in the management of metastatic RCC.

Design, setting, and participants: This was a retrospective review of patients who underwent PSMA PET/CT from 2014 to 2020 for restaging or suspected metastatic RCC in a tertiary academic setting.

Outcome measurements and statistical analysis: Management plans before and after PSMA PET/CT were recorded. Impact was classified as high (change of treatment intent, modality, or site), medium (change in treatment method), or low. Secondary outcomes included the patient-level detection rate, PSMA PET/CT parameters, sensitivity, and comparison to CT and, if available, fluorodeoxyglucose (FDG) PET/CT.

Results and limitations: Sixty-one patients met the inclusion criteria, of whom 54 (89%) had clear cell RCC. PSMA-positive disease was detected in 51 patients (84%).

* Corresponding author. Sir Peter MacCallum Department of Oncology, The University of Melbourne, 305 Grattan Street, Melbourne, VIC 3000, Australia. Tel. +61 3 8559 5000; Fax: +61 3 85597729. E-mail address: shankar.siva@petermac.org (S. Siva).
1. Introduction

Approximately 10–15% of patients with renal cell carcinoma (RCC) present with de novo metastatic disease and a further 20% eventually develop metastases [1,2]. Common sites of RCC metastases include lymph nodes, lung, bone, and liver [3]. Computed tomography (CT), magnetic resonance imaging, and ultrasound are currently recommended as imaging modalities in guidelines [4,5]. Bone scintigraphy with positron emission tomography (PET) is not established in RCC because of its limited specificity and sensitivity [4,7,8]. However, for patients with suspected recurrent RCC, PET may provide additional prognostic value over conventional imaging alone [9].

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with high expression in prostate cancer, for which it has been demonstrated that PSMA PET/CT is superior to conventional imaging [10–12]. PSMA PET/CT in prostate cancer currently has a role in de novo staging [12] and in detection of recurrent advanced disease [11], and is being investigated in the response assessment setting [13]. In addition to prostate cancer, PSMA is also expressed in the neovascularature of other solid-organ malignancies, including RCC [14]. The use of PSMA PET/CT in RCC has been evaluated, but most evidence is from case reports or small series [13,15–17].

The primary objective of this study was to assess the incremental benefit of PSMA PET/CT over CT for patients with suspected metastatic RCC regarding diagnostic findings and impact on patient management.

2. Patients and methods

2.1. Inclusion criteria

A retrospective search was conducted of all patients undergoing PSMA PET/CT at a tertiary institution between June 2014 and April 2020. Patients whose clinical details included “renal cancer”, “renal cell carcinoma”, “RCC”, or “clear cell” with the indication for the imaging for RCC were identified. Inclusion criteria included patients undergoing PSMA PET/CT for restaging or suspected metastatic RCC. All patients included had a corresponding contrast-enhanced CT scan. While PSMA PET/CT is not currently approved for RCC, we have previously reported its clinical utility [16]. Patients underwent PSMA PET/CT if it was thought that there was a potential to change management. This investigator-initiated retrospective study was approved by the local human research ethics committee with a waiver for patient consent.

2.2. Imaging

Patients were administered either $^{68}$Ga$\text{Ga}$-PSMA-11 or $^{18}$F$\text{DCFPyL}$, depending on tracer availability. For those receiving $^{68}$Ga$\text{Ga}$-PSMA-11, a weight-based dose of 2.6 MBq/kg was injected and scanning commenced approximately 60 min after injection. For those receiving $^{18}$F$\text{DCFPyL}$, a weight-based dose of 3.6 MBq/kg was injected and scanning commenced 120 min after injection. All patients were scanned using one of three General Electric Discovery PET/CT scanners (one model 690 and two model 710) and images were reconstructed using the ordered subset expectation maximisation algorithm incorporating time-of-flight.

2.3. Imaging interpretation and analysis

The number and location of metastases on CT and PSMA PET/CT were recorded. The detection rate was defined at a patient level as the presence of a finding considered to represent metastatic disease according to a review of reports by expert readers. The per-patient detection rate was used to reflect the clinical impact on a patient’s management. For PSMA PET, this was defined as intensity of uptake above background that was not considered to be physiological or due to a nonmalignant cause. A concordant finding was defined as detection of the same number of PSMA-positive CT-positive metastases in a patient. PSMA+/CT− discordance was defined as more PSMA-positive lesions, and PSMA−/CT+ discordance as more CT-positive metastases. All PSMA-positive lesions were contoured using Mimencore version 7.1 with the PETedge gradient-based lesion contouring tool ( Mim Software, Beachwood, OH, USA). The standardised uptake value (SUV) for metabolically avid disease on PSMA PET/CT was recorded and all lesions were summed.
together for measurement of total disease burden, including PSMA molecular tumour volume (MTV-PSMA) and total lesion PSMA (TLP-PSMA; MTV-PSMA × SUVmean).

2.4. Outcomes

All patients were discussed and had their imaging reviewed at an institutional genitourinary oncology multidisciplinary meeting. Management plans before and after PSMA PET/CT were recorded. A change in management was classified as a high, medium, or low impact as previously defined and published by our centre for various malignancies [18–20]. A high-impact change was defined as a change in treatment intent (eg, curative to palliative), modality (eg, systemic therapy to radiotherapy), or site. Medium impact was defined as a change in treatment method (eg, change in radiotherapy technique or dose) with no change in treatment intent, modality, or site. Low impact was defined as no change in treatment method, intent, modality, or site. Two authors (C.U. and W. L.O.) independently assessed the changes in management, and a third author (S.S.) reviewed the data if there was any disagreement. Patients with clear-cell RCC (ccRCC) and non-crRCC were compared. Owing to the wide availability of PET at our institution, clinicians frequently requested both PSMA and fluorodeoxyglucose (FDG) PET/CT imaging, primarily to identify patients with PSMA-negative FDG-positive sites of disease. Therefore, for the subgroup of patients who also had corresponding FDG PET/CT images available, the imaging characteristics between PSMA and FDG PET/CT were compared.

2.5. Statistical analysis

Descriptive statistics to summarise clinical data are reported in the form of the mean, median, standard deviation, and range for quantitative variables. Categorical variables are reported as the count and percentage. The proportion of the impact of PSMA PET/CT is described using a 95% confidence interval (CI). PSMA PET/CT was not considered beneficial if the lower limit of the 95% CI for the high impact rate was <10%. The sensitivity of imaging modalities was calculated on the basis of histopathological confirmation at a per-lesion level. The McNemar test, Wilcoxon signed-rank test, and paired t test were used to compare FDG and PSMA findings. Fisher’s exact test, an independent t test, and the Wilcoxon rank-sum test were used to compare non-crRCC and crRCC (Supplementary Table 3). All statistical analyses were performed in R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) [21].

3. Results

3.1. Patient and tumour characteristics

There were 3095 PSMA PET/CT examinations performed at our institution over the relevant time period, of which 83 were for RCC. There were 61 patients eligible for the study as they underwent PSMA PET/CT for restaging or suspected metastatic disease. The mean age was 65 yr (range 45–91 yr), with a male preponderance (56%, 34/61; Table 1). Primary management and tumour characteristics are detailed in Supplementary Table 1. The histology was crRCC in 89% of patients. Rhabdoid and/or sarcomatoid differentiation was present in 18% of patients. There were ten patients (16%) with de novo metastatic disease and 28 patients (46%) with previous metastatic disease. Seven patients (11%) had been on systemic therapy, and three patients (5%) were currently on systemic treatment. The median time from primary RCC management to CT was 31 mo (interquartile range [IQR] 9–78). The indication for undergoing PSMA PET/CT was CT-positive metastatic disease in 57 patients (94%) and suspected metastatic disease in the remaining cases.

3.2. Impact of PSMA PET/CT

Overall, 30 patients (49%) had a change in management due to PSMA PET/CT (Table 2). Of these, 29 patients (48%, 95% CI 36–60%) had a high-impact change and one (1.6%) had a medium-impact change. For these patients, the most common change was in treatment modality, which occurred for 23 patients (77%). The most common change in management was from an initial plan for metastasis-directed therapy (MDT; stereotactic ablative radiotherapy [SABR] or metastasectomy) to systemic therapy or surveillance (15 patients; Fig. 1). Nine patients for whom systemic therapy or surveillance was planned before PSMA PET/CT subsequently underwent MDT. A further four patients received SABR to additional sites and two patients received SABR to fewer sites.

3.3. Detection rate

3.3.1. Detection rate and PET characteristics

The PSMA PET/CT patient-level detection rate was 84% (n = 51). The median SUVmax was 15 (IQR 6–28), the median SUVmean was 7 (IQR 3–11), the median MTV-PSMA was 11 ml (IQR 5–29), and the median TLP-PSMA was 66 (IQR 2–242; Table 2).

3.3.2. PSMA PET/CT versus CT

There were PSMA-avid lesions on PET/CT in 84% of patients, whereas CT demonstrated lesions in 94% (p = 0.08). Of the ten patients with no PSMA-positive disease, seven had CT-positive metastases. Only one of the four CT-negative patients had PSMA-positive lesions. PSMA PET/CT and CT identified the same number of lesions in 30 patients (49%). PSMA PET/CT identified more lesions than CT in 15 patients (25%) and fewer lesions in 16 patients (26%).

| Table 1 – Patient and tumour characteristics (n = 61) |
|--------------------------------|------------------|
| Parameter                          | Result                                |
| Sex, n (%)                     | Female 27 (44)                                                                                  |
|                                 | Male 34 (56)                                                                                   |
| Mean age, yr (range)            | 65 (57–72)                                                                                     |
| Histology, n (%)                | Clear cell 54 (89)                                                                             |
|                                 | Chromophobe 2 (3)                                                                             |
|                                 | Papillary 2 (3)                                                                                 |
|                                 | Clear cell/papillary 2 (3)                                                                     |
|                                 | Unclassified variant 1 (2)                                                                     |
| Differentiation, n (%)          | None 41 (79)                                                                                    |
|                                 | Rhabdoid 5 (10)                                                                                 |
|                                 | Sarcomatoid 3 (6)                                                                              |
|                                 | Sarcomatoid/rhabdoid 3 (6)                                                                     |
|                                 | Missing 9                                                                                      |
| Previous metastases, n (%)      | Current de novo 10 (16)                                                                        |
|                                 | No 23 (38)                                                                                     |
|                                 | Yes 28 (46)                                                                                    |
| Systemic therapy, n (%)         | Current 3 (5)                                                                                  |
|                                 | Prior 7 (11)                                                                                   |
|                                 | No systemic therapy 51 (84)                                                                    |
Imaging for a patient with PSMA/CT discordant disease is shown in Figure 2. Histopathology was available in 36 patients and all had metastatic RCC confirmed.

3.3.3. PSMA PET/CT versus FDG PET/CT

A subgroup of 40 patients in our cohort had corresponding FDG PET/CT data (Supplementary Table 2). For these patients, the patient-level FDG PET/CT detection rate was 75% (30/40 patients) and the PSMA PET/CT detection rate was 88% (35/40 patients; \( p = 0.18 \)). Twenty-eight patients had PSMA-positive FDG-positive disease and three patients had PSMA-negative FDG-negative disease. Seven patients had discordant PSMA-positive FDG-negative disease and three patients had discordant PSMA-negative FDG-positive disease. Images for two patients with discordant PSMA/CT disease are shown in Figure 3. SUV characteristics were compared for the 28 patients with PSMA-positive FDG-positive disease. The SUVmax was higher for PSMA PET/CT than for FDG PET/CT (15.2 vs 8.0; \( p = 0.02 \)).

3.3.4. Subtypes and differentiation

There was no significant difference in the PSMA PET/CT detection rate between ccRCC and non-ccRCC patients (46/54, 85% vs 5/7, 71%; \( p = 0.32 \); Supplementary Table 3). The median SUVmax was higher for ccRCC than for non-ccRCC metastases (16 vs 5; \( p = 0.001 \)). There was no difference in median MTV-PSMA (ccRCC 12 ml vs non-ccRCC 8 ml; \( p = 0.81 \)). PSMA-positive ccRCC metastases had significantly higher median TLP-PSMA (74 vs 40; \( p = 0.007 \)). There was no difference in the detection rate between patients with either rhabdoid or sarcomatoid differentiation and those with no differentiation (90.9% vs 82.0%; \( p = 0.46 \)).

4. Discussion

In the context of the literature previously published (Table 3), we report the largest series to date for PSMA PET/CT in RCC. In our cohort, approximately half of the patients had a change in management as a result of PSMA PET/CT findings, with 48% classified as high impact and
1.6% as medium impact. In some cases, either PSMA PET/CT was not concordant with CT-detected metastatic disease, or detected metastases that were not identified on CT. As this was a mostly CT-positive cohort, the change in management was primarily because of the number of metastases detected rather than upstaging from M0 to M1 or downstaging from M1 to M0. This led to patients undergoing systemic therapy or surveillance rather than MDT (23%), MDT rather than surveillance (10%), or MDT for additional sites (7%). Smaller studies have observed similar results, with the most common reason for a change in management being detection of more PSMA-positive disease [22–24]. A series of 38 patients had comparable findings to our study, with a change in management for 44% in the primary setting and 41% in the restaging setting [22]. Similar to our study, the most common reason was upstaging, for two patients (12.5%) in the primary setting and five patients (23%) in the restaging setting. In two further studies of ten and 14 patients, two (20%) and three (21%) patients, respectively, had additional disease detected via PSMA PET/CT. In some of these cases the patients did not undergo MDT as planned [23,24].

We found a patient-level PSMA PET/CT detection rate of 83.6% and a CT detection rate of 93.4%. In two smaller series of 14 and five patients, the lesion-level PSMA PET/CT detection rate was 87.9–96.6% and the CT detection rate was 62.1–63.6% [24,25]. A case report described one patient with 67 ccRCC metastases, of which 55 (82.1%) were detected on CT and 66 (98.5%) on PSMA PET/CT [26]. In our cohort, the sensitivity was 91.4% for both PSMA PET/CT and CT. This differs from other studies that demonstrated superior sensitivity of 92.1–94.7% for PSMA PET/CT, compared to 68.6–78.9% for CT [23,25]. Of note, our cohort differs somewhat in that the indication for PSMA PET/CT was at the time of established radiographic disease on CT for 94% of the patients. These findings suggest that PSMA PET/CT may be used in parallel with CT for restaging and influencing further management.

We report a median SUV$_{\text{max}}$ of 15 (IQR 6–28) for PSMA-positive metastases, which is similar to other studies with a mean/median SUV$_{\text{max}}$ of 11.7–19.5 for metastases and 13.4–23.9 for the primary tumour [23,27,28]. PSMA SUV$_{\text{max}}$ may predict the grade of RCC in the primary setting, with higher median SUV$_{\text{max}}$ observed for International Society of Urological Pathology grade 3–4 (23.9) than for grade 1–2 (13.4) tumours in a cohort of 36 patients [28]. With a relatively high median SUV$_{\text{max}}$, the possibility that PSMA radioligand therapy may be useful for RCC is enticing. Trials evaluating the role of Lu-PSMA in prostate cancer have used SUV$_{\text{max}}$ of 15 or intensity greater than that for liver as a threshold for inclusion [29,30]. This may not be as effective for RCC because the uptake is in the tumour vascular endothelium and not the tumour epithelial cells, resulting in washout rather than retention, although further research is needed given the absence of quality data [13,31].

We were able to compare PSMA and FDG PET/CT in 40 patients. The only other study comparing these two modalities involved a cohort of 15 patients [32]. Similar to our findings, SUV$_{\text{max}}$ was significantly higher for PSMA PET/CT than for FDG PET/CT for both soft tissue and bone lesions. While the FDG detection rate was similar and the uptake intensity lower, FDG may still be valuable in identifying tumour heterogeneity via detection of FDG-positive PSMA-negative sites of disease. However, this only occurred in
5% of patients. It has also been shown that FDG uptake intensity is an independent prognostic factor, while there are no data on PSMA [9]. RCC constitutes a heterogeneous classification, with multiple RCC subtypes. ccRCC has the highest PSMA expression (76.2–82.5%) and papillary RCC has the lowest
In our cohort, we observed PSMA-positive metastases in 85% of patients with ccRCC (46 of 54) and 71% of patients with non-ccRCC (five of seven). Similar to the low expression in papillary RCC observed in laboratory-based studies, the only non-ccRCC cases with PSMA-negative metastases were patients with a papillary component \( (n = 2) \). However, there were another two patients with papillary RCC who did have PSMA-positive disease. There is limited evidence regarding PSMA PET/CT and non-ccRCC subtypes. A study of eight patients with non-ccRCC found that only 33% of suspicious metastases on conventional imaging had definitive or equivocal uptake \[36\]. We found that PSMA-positive ccRCC lesions had a significantly higher median SUV \(_{\text{max}}\) than PSMA-positive non-ccRCC lesions (16 vs five; \( p = 0.001 \)). Lower PET characteristics for non-ccRCC have also been observed in eight non-ccRCC cases (median SUV \(_{\text{max}}\) 3.25) and in another study with two non-ccRCC (SUV max 3.8–5.1) compared to three ccRCC cases (mean SUV \(_{\text{max}}\) 13.5, range 1.7–27.2) \[27,36\].

Limitations of our study include the retrospective nature and limited sample size. This is not an entirely homogeneous cohort, with differences in tumour, patient, and treatment characteristics. In addition, not all patients had histopathological correlation. As there are no guidelines on patients with RCC suitable for PSMA PET/CT, most patients in our cohort only had PSMA PET/CT if there was suspected metastatic disease on CT. Prospective studies are needed to ascertain the impact and detection rate of PSMA PET/CT in an unselected population. Furthermore, PET/CT may have limitations in detecting small metastases in the lungs, which are a common site of metastatic disease. In one study, all of the subcentimetre lung metastases were CT-positive but PSMA-negative \[27\]. However subcentimetre lung metastases were detected on PSMA PET-CT in another study \[25\]. In addition, we cannot draw any firm conclusions regarding patients with non-ccRCC or comparison of PSMA PET/CT with FDG PET/CT owing to the small sample size, and these outcomes should be considered exploratory.

5. Conclusions

PSMA PET/CT changed the management in a significant proportion (49%) of patients in this cohort. PSMA PET/CT in RCC can lead to either treatment intensification or de-escalation. The most frequent management changes were MDT to systemic therapy/surveillance, and systemic therapy/surveillance to MDT. Metastases had significantly higher avidity on PSMA PET/CT than on FDG PET/CT. As with any new imaging modality, caution is needed in upstaging or downstaging patients, particularly when applying treatment pathways proven on conventional imaging. PSMA PET/CT has the potential to complement CT in the diagnosis and management of suspected metastatic RCC. Similar to prostate cancer, prospective validation of PSMA PET/CT for RCC is warranted and a prospective registry at our institution is currently planned.

Author contributions: Shankar Siva and Cristian Udovocich had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Siva, Udovocich, Hofman, Callahan, Bressel.

Acquisition of data: Udovocich, Ong, Siva, Callahan.

Analysis and interpretation of data: Bressel, Siva, Udovocich, Callahan, Hofman.

Drafting of the manuscript: Udovocich, Siva, Hofman, Bressel, Callahan.

Critical revision of the manuscript for important intellectual content: Murphy, Lawrentschuk, Ong, Perera, Tran, Azad, Haran, Moon, Chandler, Shaw, Eapen, Goad.

Statistical analysis: Bressel.

Obtaining funding: None.

Administrative, technical, or material support: None.

Supervision: Siva.

Other: None.

Financial disclosures: Shankar Siva certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript...
(eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

**Funding/Support of the sponsor:** None.

**Acknowledgments:** Cristian Udovicich is the recipient of a scholarship from the Peter MacCallum Cancer Foundation. Marlon Pereira is sponsored by the Australian-America Fulbright Commission through a 2021–2022 Fulbright Future Scholarship funded by The Kinghorn Foundation. Shankar Siva is the recipient of a Cobelatch Clinical Research Fellowship from Cancer Council Victoria.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.euros.2022.08.001.

**References**

[1] National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. https://seer.cancer.gov/statfacts/html/krdrp.html.

[2] Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg U, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 2016;34:1081–6.

[3] Dudani S, de Velasco G, Wells JC, et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 2021;4:e2021869.

[4] Ljungberg B, Albiger L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019;75:799–810.

[5] National Comprehensive Cancer Network. Kidney cancer (version 4.2021). Plymouth Meeting, PA: NCCN; 2021.

[6] Gruenwald V, Eberhardt B, Bex A, et al. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol 2018;15:511–21.

[7] Vogel C, Ziegelmuller B, Ljungberg B, et al. Imaging in suspected renal-cell carcinoma: systematic review. Clin Genitourin Cancer 2019;17:e345–55.

[8] Capogrosso P, Capitano U, La Croce G, et al. Follow-up after treatment for renal cell carcinoma: the evidence beyond the guidelines. Eur Urol Focus 2016;1272–81.

[9] Alongi P, Picchio M, Zattoni F, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging 2016;43:464–73.

[10] Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81–5.

[11] Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and discrimination of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur J Nucl Med 2020;77:403–17.

[12] Hofman MS, LawrenceTschu N, Francis RJ, et al. Prostate-specific membrane antigen PET/CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395:1208–16.

[13] Siva S, Udovicich C, Tran B, Zargar H, Murphy DG, Hofman MS. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. Nat Rev Urol 2020;17:107–18.

[14] Chang SS, O’Keefe DS, Bach J, Reuter VE, Heston WD, Gauduin PB. Prostate-specific membrane antigen is produced in tumors-associated neovascularisation. Clin Cancer Res 1999;5:2674–81.

[15] Ahn T, Roberts MJ, Abduljabar A, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol 2019;21:799–807.

[16] Siva S, Callahan J, Pryor D, Martin J, LawrenceSku N, Hofman MS. Utility of 68Ga prostate specific membrane antigen-positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol 2017;61:372–8.

[17] Evangelista L, Basso U, Maruzzo M, Novara G, The Role of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for the evaluation of renal cancer. Eur Urol Focus 2020;6:146–50.

[18] Siva S, Byrne K, Seel M, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. J Nucl Med 2013;54:1223–9.

[19] Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med 2012;53:864–71.

[20] Hicks RJ, Kalff V, MacManus MP, et al. The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001;42:1605–13.

[21] R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.

[22] Raveenthiran S, Esler R, Yazley J, Kyle S. The use of 68Ga-PSMA-CT in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46:2280–8.

[23] Rhee H, Blazak J, Tham CM, et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res 2016;6:76.

[24] Meyer AR, Carducci MA, Denmeade SR, et al. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann N Y Acad Sci 2019;1433:617–23.

[25] Rowe SP, Gorin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med 2015;29:877–82.

[26] Gorin MA, Rowe SP, Hooper JE, et al. PSMA-targeted 18F-DCFPyL PET/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy. Eur Urol 2017;71:145–6.

[27] Savicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging 2017;44:102–7.

[28] Gao J, Xu Q, Fu Y, et al. Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2021;48:561–9.

[29] Hofman MS, Emmett L, Sandhu S, et al. 177Lu-Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021;397:797–804.

[30] Sartor O, de Bono J, Chi KN, et al. Duterte-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385:1091–103.

[31] Uijen MJM, Derks YHW, Merkx RJJ, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging 2021;48:4350–68.

[32] Liu Y, Wang G, Yu H, et al. Comparison of 18F-DCFPyL and 18F-FDG PET/CT/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients. Nucl Med Commun 2020;41:1299–305.

[33] Bacalla A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovascularisation of renal neoplasms. Urology 2007;70:385–90.

[34] Spatz S, Tolkach Y, Jung K, et al. Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol 2018;199:370–7.

[35] Al-Abdalmad HA, Olga S, Gregor PD, et al. Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol 2008;21:727–32.

[36] Yin Y, Campbell SP, Markowski MC, et al. Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Mol Imaging Biol 2019;21:567–73.
[37] Mittlmeier LM, Unterrainer M, Rodler S, et al. 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. Eur J Nucl Med Mol Imaging 2021;48:2031–7.

[38] Gühne F, Seifert P, Theis B, Steinert M, Freesmeyer M, Drescher R. PSMA-PET/CT in patients with recurrent clear cell renal cell carcinoma: histopathological correlations of imaging findings. Diagnostics 2021;11:1142.

[39] Golan S, Aviv T, Groshar D, et al. Dynamic 68Ga-PSMA-11 PET/CT for the primary evaluation of localized renal mass: a prospective study. J Nucl Med 2021;62:773–8.

[40] Tariq A, Kwok M, Pearce A, et al. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: a multi-institutional case series with intra-individual comparison. Urol Oncol 2022;40:66.e1–9.

[41] Meng L, Zhang S, Gao J, et al. [68Ga]Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF-2α expression and therapeutic response to HIF-2α antagonists in patients with RCC. Eur Radiol. In press. https://doi.org/10.1007/s00330-022-08738-y.

[42] Tariq A, McGeorge S, Pearce A, et al. Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urol Oncol 2022;40:276.e1–9.